We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

179 hedge funds and large institutions have $826M invested in Acorda Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more call options, than puts

Call options by funds: $38.5M | Put options by funds: $15.2M

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

16% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 55

3% more funds holding

Funds holding: 174 → 179 (+5)

19% less capital invested

Capital invested by funds: $1.01B → $826M (-$189M)

Holders
179
Holders Change
+5
Holders Change %
+2.87%
% of All Funds
3.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
64
Reduced
55
Closed
19
Calls
$38.5M
Puts
$15.2M
Net Calls
+$23.3M
Net Calls Change
-$2.58M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$16.5M
2
BlackRock
BlackRock
New York
+$15.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
4
Marshall Wace
Marshall Wace
United Kingdom
+$7.23M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.58M

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$29.3M
2
Bank of America
Bank of America
North Carolina
-$7.81M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.62M
4
Deutsche Bank
Deutsche Bank
Germany
-$4.82M
5
First Trust Advisors
First Trust Advisors
Illinois
-$3.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
151
Royal Bank of Canada
Ontario, Canada
$44K +$23.9K +11 +85%
OAM
152
Oppenheimer Asset Management
New York
$44K +$50K +23 New
Macquarie Group
153
Macquarie Group
Australia
$37K -$32.6K -15 -43%
LTFS
154
Ladenburg Thalmann Financial Services
Florida
$34K – – –
Bank of Montreal
155
Bank of Montreal
Ontario, Canada
$34K +$19.6K +9 +100%
RA
156
Royce & Associates
New York
$26K +$2.18K +1 +8%
LIA
157
LS Investment Advisors
Michigan
$22K -$2.18K -1 -8%
VCM
158
Versant Capital Management
Arizona
$19K +$2.18K +1 +10%
PNC Financial Services Group
159
PNC Financial Services Group
Pennsylvania
$18K -$10.9K -5 -33%
PHK
160
Point72 Hong Kong
Hong Kong
$18K +$17.4K +8 +800%
BNP Paribas Financial Markets
161
BNP Paribas Financial Markets
France
$16.5K -$272K -125 -93%
FWM
162
Focused Wealth Management
New York
$16K – – –
MOACM
163
Mutual of America Capital Management
New York
$15K +$4.35K +2 +33%
PCM
164
Prelude Capital Management
New York
$12K +$2.18K +1 +20%
SWA
165
Sutton Wealth Advisors
Florida
$11.1K +$2.18K +1 +20%
FHB
166
First Hawaiian Bank
Hawaii
$11K +$13.1K +6 New
AG
167
Advisor Group
Arizona
$10K -$4.35K -2 -29%
CG
168
Cutler Group
California
$10K -$2.18K -1 -14%
TRCT
169
Tower Research Capital (TRC)
New York
$5K -$8.7K -4 -57%
Schroder Investment Management Group
170
Schroder Investment Management Group
United Kingdom
$4.41K +$5.03M +2,310 +4,915%
Daiwa Securities Group
171
Daiwa Securities Group
Japan
$4K – – –
Nisa Investment Advisors
172
Nisa Investment Advisors
Missouri
$4K – – –
WT
173
Whittier Trust
California
$4K – – –
PAMU
174
Pictet Asset Management (UK)
United Kingdom
$2.48K +$920K +423 +47%
GT
175
Glenmede Trust
Pennsylvania
$2.23K – – –
4 5 6
7
8

ACOR Hedge Fund Activity: Q4 2018 in Review

179 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2018, worth a combined $826M — down 19% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 19 closed out — a net gain of 7 holders — while 64 added to existing stakes and 55 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $16.5M. The largest seller was Scopia Capital Management, cutting an estimated $29.3M.

  • 179 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2018, up from 174 in Q3 2018.
  • Funds reported $826M of Acorda Therapeutics stock for Q4 2018, down 19% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q4 2018 and 19 closed out, a net change of +7 holders.
  • The largest Acorda Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $16.5M added.
  • The largest Acorda Therapeutics seller in Q4 2018 was Scopia Capital Management, an estimated $29.3M sold.

Based on aggregated 13F filings for Q4 2018.